OMED

OncoMed Pharmaceuticals, Inc.

OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

89 hedge funds and large institutions have $189M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 14 reducing their positions, and 8 closing their positions.

2019 Q3 2019 Q2 2019 Q1 2018 Q4 2018 Q3 2018 Q2 2018 Q1 2017 Q4 2017 Q3 2017 Q2 2017 Q1 2016 Q4 2016 Q3 2016 Q2 2016 Q1 2015 Q4 2015 Q3 2015 Q2 2015 Q1 2014 Q4 2014 Q3 2014 Q2 2014 Q1 2013 Q4 2013 Q3

Holders

Holders Change

Holders Change %

+5.95%

% of All Funds

2.38%

Holding in Top 10

Holding in Top 10 Change

Holding in Top 10 Change %

+50%

% of All Funds

0.08%

New

Increased

Reduced

Closed

Calls

$1.84M

Puts

$1.18M

Net Calls

+$658K

Net Calls Change

+$476K

Top Buyers

1	1 Primecap Management Pasadena, California	$14.9M
2	IHM 2 Iguana Healthcare Management New York	$16.6M
3	3 Franklin Resources San Mateo, California	$11.4M
4	BI 4 BVF Inc San Francisco, California	$20.7M
5	5 Alyeska Investment Group Chicago, Illinois	$9.96M

Top Sellers

1	TC 1 TFS Capital West Chester, Pennsylvania	$0
2	2 Handelsbanken Fonder Stockholm, Sweden	$0
3	NFA 3 Nationwide Fund Advisors Columbus, Ohio	$151K
4	4 Barclays London, United Kingdom	$966K
5	5 Jacobs Levy Equity Management Florham Park, New Jersey	$0

#	Name	Market Value	Shares	Shares Change	Shares Change %
26	CS 26 Credit Suisse Zurich, Switzerland	$1.05M	91,821	-15,708	-15%
27	27 Deutsche Bank Frankfurt Am Main Ge, Germany	$1.04M	91,034	+46,674	+105%
28	28 Morgan Stanley New York	$1.01M	88,516	+63,302	+251%
29	BIM 29 BlackRock Investment Management Wilmington, Delaware	$982K	85,924	+22,967	+36%
30	ACA 30 Avoro Capital Advisors New York	$972K	85,000	+85,000	New
31	31 Barclays London, United Kingdom	$966K	84,595	-17,338	-17%
32	GPCM 32 Granite Point Capital Management Boston, Massachusetts	$910K	79,650	-12,200	-13%
33	33 Charles Schwab San Francisco, California	$837K	73,224	+30,403	+71%
34	BC 34 Birchview Capital Burlington, Vermont	$808K	70,689	–	–
35	NSEDCP 35 NJ State Employees Deferred Compensation Plan Trenton, New Jersey	$800K	70,000	–	–
36	QI 36 QS Investors New York	$735K	64,307	–	–
37	37 Wells Fargo San Francisco, California	$566K	49,536	+36,910	+292%
38	AA 38 ALPS Advisors Denver, Colorado	$523K	45,747	+3,185	+7%
39	39 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$514K	44,933	+8,200	+22%
40	HCM 40 Highbridge Capital Management New York	$493K	43,118	+43,118	New
41	HCM 41 Hodges Capital Management Dallas, Texas	$400K	35,000	–	–
42	42 Goldman Sachs New York	$360K	31,486	+4,394	+16%
43	RC 43 Randolph Company Cincinnati, Ohio	$345K	30,150	+30,150	New
44	TAM 44 Tocqueville Asset Management New York	$327K	28,600	–	–
45	TA 45 Teachers Advisors New York	$314K	27,462	–	–
46	46 Swiss National Bank Zurich, Switzerland	$311K	27,200	+13,000	+92%
47	47 ProShare Advisors Bethesda, Maryland	$290K	25,395	+700	+3%
48	48 Simplex Trading Chicago, Illinois	$282K	24,677	+21,489	+674%
49	PP 49 PDT Partners New York	$277K	24,200	-300	-1%
50	SO 50 STRS Ohio Columbus, Ohio	$264K	23,100	-900	-4%

OncoMed Pharmaceuticals, Inc. OMED

Top Buyers

Top Sellers

OncoMed Pharmaceuticals, Inc.

OMED